Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2010
08/19/2010WO2010093904A2 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
08/19/2010WO2010093859A1 Material and methods for treating developmental disorders including comorbid and idiopathic autism
08/19/2010WO2010093736A1 Method for facilitating extinction training using d-cycloserine
08/19/2010WO2010093727A1 Quinazolinones as prolyl hydroxylase inhibitors
08/19/2010WO2010093627A2 Fibronectin type iii domain based scaffold compositions, methods and uses
08/19/2010WO2010093425A1 Histamine h3 inverse agonists and antagonists and methods of use thereof
08/19/2010WO2010093284A1 Dipeptide mimetics of ngf and bdnf neurotrophins
08/19/2010WO2010093070A1 Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
08/19/2010WO2010093061A1 Diazepinedione derivative
08/19/2010WO2010092966A1 Novel triazine derivative and pharmaceutical composition containing same
08/19/2010WO2010092660A1 Inhibitor of casein kinase 1δ and casein kinase 1ε
08/19/2010WO2010092485A2 Combined treatment of multiple sclerosis
08/19/2010WO2010092419A1 Combined treatment of multiple sclerosis
08/19/2010WO2010092317A1 Nmnat2 modulator
08/19/2010WO2010092287A1 N-[(6-azabicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
08/19/2010WO2010092286A1 N-[(2-azabicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
08/19/2010WO2010092181A1 Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
08/19/2010WO2010092180A1 Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
08/19/2010WO2010092162A1 Neuroactive plant extract from hypericum polyanthemum
08/19/2010WO2010092043A1 Phenoxy acetic acid derivatives
08/19/2010WO2010092015A1 Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
08/19/2010WO2010091981A2 Products comprising n-phenylpropenoyl amino acid amides and uses thereof
08/19/2010WO2010091540A1 A sulphonyl tetrazole compound, its preparation method and its use for preparing laetispicine
08/19/2010WO2010075280A3 Coumarin-based compounds for the treatment of alzheimer's disease and cancer
08/19/2010WO2010075263A3 Compounds and methods for enhancing erythropoiesis
08/19/2010WO2010075255A3 Methods for treating or preventing cancer and neurodegenerative diseases
08/19/2010WO2010074607A3 Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance
08/19/2010WO2010056985A9 Treatment of proteinopathies using a farnesyl transferase inhibitor
08/19/2010WO2010056754A3 Inhibition of mammalian target of rapamycin
08/19/2010WO2010054068A3 Cyclic adenosine monophosphates for reducing the formation of adhesions
08/19/2010WO2010048273A3 Methods and compounds for treatment of neurodegenerative disorders
08/19/2010WO2010042780A3 Methods and compositions for treating status epilepticus and seizures causing status epilepticus
08/19/2010WO2010033249A3 Compositions of and methods of using ligand dimers
08/19/2010WO2010026596A3 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses
08/19/2010WO2010023197A3 Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
08/19/2010WO2010023196A3 Piperidylpropionamide derivatives useful for the treatment of cns disorders including depression and panic disorder
08/19/2010WO2009135581A3 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
08/19/2010WO2009109908A8 Methods of treating inflammatory pain
08/19/2010WO2009064747A3 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain
08/19/2010US20100210839 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes
08/19/2010US20100210838 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity
08/19/2010US20100210818 Nucleic acids encoding the human alex1 protein
08/19/2010US20100210732 Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
08/19/2010US20100210731 Modafinil Compositions
08/19/2010US20100210727 Hepoxilin analog enantiomers
08/19/2010US20100210726 Composition for promoting ketone body production
08/19/2010US20100210719 O-desmethylvenlafaxine
08/19/2010US20100210709 Methods of Treatment of Opioid Tolerance, Physical Dependence, Pain and Addiction With Inhibitors of Certain Growth Factor Receptors
08/19/2010US20100210705 Pyrrole and Isoindole Carboxamide Derivatives as P2X7 Modulators
08/19/2010US20100210693 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
08/19/2010US20100210690 N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators
08/19/2010US20100210687 Compounds which have activity at M1 receptor and their uses in medicine
08/19/2010US20100210685 Novel Substituted Indoles
08/19/2010US20100210680 Tricyclic heterocyclic derivatives
08/19/2010US20100210676 Chemically Modified Small Molecules
08/19/2010US20100210675 Solvent-free crystalline form of naltrexone
08/19/2010US20100210672 Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
08/19/2010US20100210671 Quinazolinone T-Type Calcium Channel Antagonists
08/19/2010US20100210667 Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
08/19/2010US20100210664 Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
08/19/2010US20100210663 Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity
08/19/2010US20100210661 Stat3/5 activation inhibitor
08/19/2010US20100210659 Pyrrolidine derivatives as nk3 receptor antagonists
08/19/2010US20100210658 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
08/19/2010US20100210651 Isoxazole-isoxazoles and isoxazole-isothiazoles
08/19/2010US20100210647 Indole compounds as an inhibitor of cellular necrosis
08/19/2010US20100210646 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
08/19/2010US20100210642 Acetylenyl-pyrazolo-pyrimidine derivatives
08/19/2010US20100210640 Benzamide derivatives, their preparation and uses in medicine thereof
08/19/2010US20100210638 Modulators of atp-binding cassette transporters
08/19/2010US20100210637 Heteroaryloxy nitrogenous saturated heterocyclic derivative
08/19/2010US20100210635 Renin inhibitors
08/19/2010US20100210631 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
08/19/2010US20100210627 Pyrazine compounds, their use and methods of preparation
08/19/2010US20100210626 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
08/19/2010US20100210625 Novel1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands
08/19/2010US20100210624 Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
08/19/2010US20100210620 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers
08/19/2010US20100210604 Zwitterion solution for low-volume therapeutic delivery
08/19/2010US20100210597 C21-Deoxy Ansamycin Derivatives as Antitumor Agents
08/19/2010US20100210593 Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
08/19/2010US20100210592 Amines or amino alcohols as glyt1 inhibitors
08/19/2010US20100210590 Compositions and treatments for seizure-related disorders
08/19/2010US20100210572 Hydrolysate of crocin
08/19/2010US20100210564 Drug or food containing a peptide
08/19/2010US20100210560 Neurotensin receptor agonists and opioid receptor agonists
08/19/2010US20100210559 Trap-14 as a therapeutic agent
08/19/2010US20100210556 Use of a peptide as a therapeutic agent
08/19/2010US20100210554 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
08/19/2010US20100210553 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent
08/19/2010US20100210552 Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions
08/19/2010US20100210547 Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
08/19/2010US20100210542 Methods of Treating Disorders with Group I mGluR Antagonists
08/19/2010US20100210539 Use of peptide ll-37 as a therapeutic agent
08/19/2010US20100210537 Use of a defensin peptide as a therapeutic agent
08/19/2010US20100210535 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof
08/19/2010US20100210532 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent
08/19/2010US20100210524 Novel estrogen receptor ligands
08/19/2010US20100210523 Modulation of activity of proneurotrophins
08/19/2010US20100210521 Compositions and methods for modulating ampa receptor-mediated excitotoxicity
1 ... 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 ... 1833